Select Opportunities

• Phase 3-stage first in class oral visual cycle modulator for Stargardt disease

• Phase 2-stage first in class silk-derived protein-4 eyedrops for DED, superior limbic keratoconjunctivitis, and ocular inflammation

• Phase 1-stage first in class oral mitochondrial ATF4-ISR pathway modulator for r/r B-cell lymphomas, leukemias, and solid tumors

• Phase 1-stage first in class antibody for solid tumors

• Phase 1-stage first in class DNA polymerase β Inhibitor for cholangiocarcinoma and solid tumors

• IND-stage best in class oral PIM kinase inhibitors for RA, lupus, and orphan autoimmune diseases

• Preclinical-stage best in class oral VAP-1 inhibitors for neuroinflammation, MASH, and DME

• Preclinical-stage best in class oral phosphopantothenate replacement therapy for pantothenate kinase-associated neurodegeneration (PKAN)    

• Preclinical-stage first in class oral compounds for obesity, metabolic disorders, and longevity